Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Phosphorylation
100%
Epithelial Ovarian Cancer
100%
Dual Inhibition
100%
Ablating
100%
Recurrent Ovarian Carcinoma
100%
PARP Inhibitor (PARPi)
77%
Human Ovarian Cancer Cell
33%
Cell-derived
22%
Synergize
22%
Ovarian Cancer Patients
22%
Platinum Resistance
22%
Olaparib
22%
Patient-derived Organoids
22%
DNA Repair
11%
Immunohistochemistry
11%
DNA Damage
11%
Apoptosis
11%
Low Response
11%
Clinical Utility
11%
Xenograft
11%
Pharmacological Inhibitors
11%
Cisplatin
11%
Complete Response
11%
Chemoresistant
11%
IC50
11%
Focus Formation
11%
Disease Stage
11%
In Vitro Production
11%
Survival Outcomes
11%
Poor Survival
11%
Resistance Emergence
11%
Patient-derived Models
11%
Platinum Sensitivity
11%
Combination Strategy
11%
Homologous Recombination Deficiency
11%
BRCA Status
11%
BRCA-deficient Cancers
11%
BRCA Deficiency
11%
Medicine and Dentistry
Krukenberg Tumor
100%
Poly ADP Ribose Polymerase
100%
PARP Inhibitor
46%
Cancer Cell
23%
Organoid
15%
Olaparib
15%
Diseases
7%
Cell Line
7%
Malignant Neoplasm
7%
Immunohistochemistry
7%
In Vitro
7%
Xenograft
7%
Ex Vivo
7%
Programmed Cell Death
7%
Cisplatin
7%
IC50
7%
DNA Damage
7%
Homologous Recombination
7%
DNA Repair
7%
Recombination Repair
7%